Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Spinraza
Spinraza
Spinal Muscular Atrophy: Four trials to watch over the next 12 months
Spinal Muscular Atrophy: Four trials to watch over the next 12 months
Clinical Trials Arena
clinical trials
spinal muscular atrophy
Scholar Rock
apitegromab
Novartis
Zolgensma
Spinraza
clenbuterol
Flag link:
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Fierce Pharma
Biogen
Alcyone Therapeutics
SMA
Spinraza
devices
Medtech
Flag link:
Biogen Announces New Spinraza Data Ahead of Presentation
Biogen Announces New Spinraza Data Ahead of Presentation
BioSpace
Biogen
Spinraza
SMA
spinal muscular atrophy
Flag link:
Biogen brings in a successor to Spinraza
Biogen brings in a successor to Spinraza
BioPharma Dive
Biogen
Ionis Pharmaceuticals
Spinraza
BIIB115
antisense
spinal muscular atrophy
Flag link:
Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial
Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial
Fierce Pharma
Biogen
Spinraza
SMA
Roche
Evrysdi
spinal muscular atrophy
Flag link:
Zolgensma flatlines, but Spinraza isn’t the beneficiary
Zolgensma flatlines, but Spinraza isn’t the beneficiary
EP Vantage
SMA
Biogen
Novartis
Roche
Spinraza
Zolgensma
Evrysdi
Flag link:
Biogen Reports New Spinraza Data in SMA
Biogen Reports New Spinraza Data in SMA
Global Genes
Biogen
Spinraza
SMA
Flag link:
2 Fumbles and 1 Gift in Biogen's Latest Earnings Report
2 Fumbles and 1 Gift in Biogen's Latest Earnings Report
Motley Fool
Biogen
earnings
Spinraza
Flag link:
Biogen is running out of safety nets
Biogen is running out of safety nets
BioPharma Dive
Biogen
Vumerity
Tecfidera
Spinraza
aducanumab
Flag link:
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
SMA
spinal muscular atrophy
Novartis
Zolgensma
Spinraza
Roche
Evrysdi
Flag link:
Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”
Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”
BioSpace
Biogen
SMA
spinal muscular atrophy
Spinraza
clinical trials
Flag link:
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
MedCity News
Biogen
clinical trials
Spinraza
Novartis
Zolgensma
SMA
spinal muscular atrophy
Flag link:
Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients
Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients
BioSpace
Biogen
SMA
Spinraza
clinical trials
Flag link:
Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst
Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst
Fierce Pharma
Roche
FDA
risdiplam
Biogen
Spinraza
Novartis
Zolgensma
SMA
Flag link:
Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents
Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents
Fierce Pharma
Biogen
SMA
Spinraza
COVID-19
Flag link:
Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis
Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis
Endpoints
Roche
PTC Therapeutics
SMA
risdiplam
Biogen
Spinraza
Flag link:
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Investors Business Daily
Wave Life Sciences
suvodirsen
DMD
Merck
Keytruda
Biogen
Spinraza
Zoetis
Europe
animal health
Jazz Pharmaceuticals
JZP-258
narcolepsy
Flag link:
Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Fierce Pharma
Biogen
clinical trials
Spinraza
SMA
spinal muscular atrophy
Novartis
Flag link:
Threats to Spinraza are mounting, but Biogen still has cards to play
Threats to Spinraza are mounting, but Biogen still has cards to play
EP Vantage
Biogen
SMA
Spinraza
Novartis
Roche
risdiplam
Zolgensma
Flag link:
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Roche
PTC Therapeutics
spinal muscular atrophy
risdiplam
Novartis
Zolgensma
Biogen
Spinraza
Flag link:
Pages
1
2
3
next ›
last »